Live
- 10 Tried-and-Tested Home Remedies for Toothaches
- Thila Taila Abhishekah Pooja to Lord Shaneswara
- Priyanka Gandhi says BJP talking of 'tinkering' with Constitution with PM’s nod
- ‘Kalki 2898 AD’ locks release date; film to entertain audience from June last week
- LS polls: PM Modi says BJP-NDA leading 2-0 after first two phases
- Plea in Madras HC seeks special polling arrangement for names 'missing' from Coimbatore voter list
- Ex CM KCR Bus tour on 4 th day
- Youth National Games 2024 kick-start in Delhi; over 5,000 athletes from 15 states vying for top honours
- TN Police warn people against fraudsters using AI-based voice cloning
- L-G office blames Saurabh Bharadwaj for delay in enhancing MCD Commissioner's financial powers
Doctor's medical device gets patent
Dr. Nageswara Rao Koneti
A medical device designed and developed by city cardiologist and Director, Rainbow Children’s Heart Institute, Dr. Nageswara Rao Koneti, and his team, to treat Ventricular Septal Defect (VSD), which is a hole between two lower chambers (ventricles) of heart, has received Indian patent
Hyderabad: A medical device designed and developed by city cardiologist and Director, Rainbow Children's Heart Institute, Dr. Nageswara Rao Koneti, and his team, to treat Ventricular Septal Defect (VSD), which is a hole between two lower chambers (ventricles) of heart, has received Indian patent.
Dubbed as KONAR-MF (KOneti NAgeswara Rao- Multi Functional) occlude, the medical device had earlier received European EC approval in 2019 while Euro-African, Korean patents were granted in 2021 and 2022. The Indian patent was granted after several critical examinations in February 2023, a press release said.
Dr. Rao and his team have been working since 2009 to develop the technique and the appropriate occluder for the transcatheter device closure of VSDs. The early results were presented in American college of cardiology meeting at Chicago, USA in 2012.
At present, the device is available commercially through Lifetech Scientific Company, Schengen and has benefitted more than 10,000 patients in last three-years in more than 72 countries including Germany, Italy, UK, USA and Japan, the press release added.
